AstraZeneca and TerSera Therapeutics LLC (TerSera) have entered a agreement that gives TerSera the commercial rights to Zoladex in the United States and Canada.
“This agreement allows us to retain a significant share of the value of Zoladex in the US and Canada, while concentrating our resources on our innovative New Oncology medicines,” Mark Mallon, AstroZeneca's executive vice president of Global Product & Portfolio Strategy at AstraZeneca, said in a statement. “It also ensures patients have continued access to Zoladex, with TerSera’s dedicated focus helping to expand the potential of this important medicine.”
Zoladex, an injectable luteinizing hormone-releasing hormone agonist, was first approved in the United States and Canada in 1989. The drug treats prostate cancer, breast cancer and certain benign gynecological disorders. TerSera will pay AstraZeneca $250 million for the rights, as well as up to $70 million for sales-related income milestones and a recurring quarterly sales-based payment.
“We are very pleased to be partnering with AstraZeneca, and investing in the future growth of Zoladex, which continues to be a mainstay of treatment for its indicated uses,” TerSera Therapeutics Chairman and CEO Ed Fiorentino said.